Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc.filedCriticalPfizer Inc.
Priority to YU97992ApriorityCriticalpatent/YU48914B/sh
Publication of YU97992ApublicationCriticalpatent/YU97992A/sh
Publication of YU48914BpublicationCriticalpatent/YU48914B/sh
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Indole Compounds
(AREA)
Thiazole And Isothizaole Compounds
(AREA)
Abstract
(1S)-5-[4-(3-(5-metil-2-fenil-4-oksazolil)-1-hidroksi-propil)benzil-tiazolidin-2,4-dion, nazna čen time, što je njegova struktura predstavljena formulom I, u kojoj je jedinjenje formule I u osnovi oslobođeno svog odgovarajućeg 1R enantiomera, njegove farmaceutski prihvatljive katjonske soli, i njegove farmaceutski prihvatljive adicione soli sa kiselinom. Prijava sadrži još 2 nezavisna i 12 zavisnih zahteva.
YU97992A1992-11-131992-11-13Hipoglikemski tiazolidindioni i intermedijari
YU48914B
(sh)
3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
Производные бензоксазола в виде рацемата или отдельных энантиомеров и их фармацевтически приемлемые соли и фармацевтические композиции с ингибирующей биосинтез лейкотриенов активностью
Menetelmä (-)-N-metyyli-N-(4-(4-fenyyli-4-asetyyliaminopiperidiini-1-yl)-2-(3,4-diklorofenyyli)butyyli)bentsamidi ja sen farmaseuttisesti hyväksyttäviä suoloja